Home - Products - Others - Other Targets - Ciprofloxacin EP IMpurity A

Ciprofloxacin EP IMpurity A

CAS No. 86393-33-1

Ciprofloxacin EP IMpurity A( —— )

Catalog No. M16259 CAS No. 86393-33-1

Used as a new type of quinoline anti-bacterial drug ciprofloxacin intermediate.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
500MG	67	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Ciprofloxacin EP IMpurity A
Note

Research use only, not for human use.
Brief Description

Used as a new type of quinoline anti-bacterial drug ciprofloxacin intermediate.
Description

Used as a new type of quinoline anti-bacterial drug ciprofloxacin intermediate.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Others
Research Area

——
Indication

——

Chemical Information

CAS Number

86393-33-1
Formula Weight

281.67
Molecular Formula

C13H9ClFNO3
Purity

>98% (HPLC)
Solubility

Limited solubility
SMILES

OC(=O)C1=CN(C2CC2)C2=CC(Cl)=C(F)C=C2C1=O
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Protein Kinase C (19...

Protein Kinase C (19-31) TFA, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate peptide for testing the protein kinase C activity.
Pyrazolo[1,5-a]pyrim...

Detail unknown.
CCCP

CCCP inhibits activation of STING and its downstream signalling molecules, TBK1 and IRF3. CCCP inhibits STING-mediated IFN-β production via disrupting mitochondrial membrane potential (MMP).

Sign In Join Free